Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 8.11
INFI's Cash to Debt is ranked lower than
57% of the 895 Companies
in the Global Biotechnology industry.

( Industry Median: 27.79 vs. INFI: 8.11 )
Ranked among companies with meaningful Cash to Debt only.
INFI' s Cash to Debt Range Over the Past 10 Years
Min: 0.28  Med: 5827.34 Max: 13254
Current: 8.11
0.28
13254
Equity to Asset 0.40
INFI's Equity to Asset is ranked lower than
78% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. INFI: 0.40 )
Ranked among companies with meaningful Equity to Asset only.
INFI' s Equity to Asset Range Over the Past 10 Years
Min: -0.03  Med: 0.65 Max: 0.94
Current: 0.4
-0.03
0.94
Z-Score: -1.55
M-Score: 107.44
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -121.77
INFI's Operating margin (%) is ranked lower than
56% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -70.14 vs. INFI: -121.77 )
Ranked among companies with meaningful Operating margin (%) only.
INFI' s Operating margin (%) Range Over the Past 10 Years
Min: -6986.21  Med: -91.69 Max: 22.94
Current: -121.77
-6986.21
22.94
Net-margin (%) -124.14
INFI's Net-margin (%) is ranked lower than
57% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -66.97 vs. INFI: -124.14 )
Ranked among companies with meaningful Net-margin (%) only.
INFI' s Net-margin (%) Range Over the Past 10 Years
Min: -6967.24  Med: -68.67 Max: 28.35
Current: -124.14
-6967.24
28.35
ROE (%) -81.57
INFI's ROE (%) is ranked lower than
76% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: -31.22 vs. INFI: -81.57 )
Ranked among companies with meaningful ROE (%) only.
INFI' s ROE (%) Range Over the Past 10 Years
Min: -123.36  Med: -41.36 Max: 27.59
Current: -81.57
-123.36
27.59
ROA (%) -40.28
INFI's ROA (%) is ranked lower than
61% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. INFI: -40.28 )
Ranked among companies with meaningful ROA (%) only.
INFI' s ROA (%) Range Over the Past 10 Years
Min: -51.92  Med: -27.61 Max: 16.29
Current: -40.28
-51.92
16.29
ROC (Joel Greenblatt) (%) -387.47
INFI's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -378.42 vs. INFI: -387.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
INFI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3134.63  Med: -394.00 Max: 418.86
Current: -387.47
-3134.63
418.86
Revenue Growth (3Y)(%) -0.90
INFI's Revenue Growth (3Y)(%) is ranked lower than
53% of the 440 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. INFI: -0.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
INFI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -100  Med: -4.60 Max: 155.9
Current: -0.9
-100
155.9
EBITDA Growth (3Y)(%) -55.50
INFI's EBITDA Growth (3Y)(%) is ranked lower than
94% of the 454 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. INFI: -55.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
INFI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -64.6  Med: 12.25 Max: 261.4
Current: -55.5
-64.6
261.4
EPS Growth (3Y)(%) -38.00
INFI's EPS Growth (3Y)(%) is ranked lower than
86% of the 462 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. INFI: -38.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
INFI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -64.1  Med: 12.40 Max: 116
Current: -38
-64.1
116
» INFI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

INFI Guru Trades in Q4 2014

Steven Cohen 52,476 sh (New)
Jim Simons 201,600 sh (+371.03%)
Steven Cohen Sold Out
Chuck Royce Sold Out
Paul Tudor Jones 12,679 sh (-21.56%)
» More
Q1 2015

INFI Guru Trades in Q1 2015

Lee Ainslie 17,200 sh (New)
Jim Simons 668,000 sh (+231.35%)
Paul Tudor Jones Sold Out
» More
Q2 2015

INFI Guru Trades in Q2 2015

Paul Tudor Jones 18,900 sh (New)
Jim Simons 1,198,350 sh (+79.39%)
Lee Ainslie Sold Out
» More
Q3 2015

INFI Guru Trades in Q3 2015

Paul Tudor Jones 21,600 sh (+14.29%)
Jim Simons 877,500 sh (-26.77%)
» More
» Details

Insider Trades

Latest Guru Trades with INFI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 10.38
INFI's Forward P/E is ranked higher than
74% of the 343 Companies
in the Global Biotechnology industry.

( Industry Median: 16.89 vs. INFI: 10.38 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.10
INFI's P/B is ranked higher than
62% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. INFI: 2.10 )
Ranked among companies with meaningful P/B only.
INFI' s P/B Range Over the Past 10 Years
Min: 0.68  Med: 3.08 Max: 51.23
Current: 2.1
0.68
51.23
P/S 2.72
INFI's P/S is ranked higher than
83% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 9.13 vs. INFI: 2.72 )
Ranked among companies with meaningful P/S only.
INFI' s P/S Range Over the Past 10 Years
Min: 1.32  Med: 4.37 Max: 60.95
Current: 2.72
1.32
60.95
EV-to-EBIT -1.09
INFI's EV-to-EBIT is ranked lower than
99.99% of the 450 Companies
in the Global Biotechnology industry.

( Industry Median: 20.72 vs. INFI: -1.09 )
Ranked among companies with meaningful EV-to-EBIT only.
INFI' s EV-to-EBIT Range Over the Past 10 Years
Min: -265.5  Med: -2.70 Max: 10.9
Current: -1.09
-265.5
10.9
EV-to-EBITDA -1.11
INFI's EV-to-EBITDA is ranked lower than
99.99% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 18.13 vs. INFI: -1.11 )
Ranked among companies with meaningful EV-to-EBITDA only.
INFI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -91.9  Med: -2.70 Max: 782
Current: -1.11
-91.9
782
Current Ratio 4.04
INFI's Current Ratio is ranked lower than
54% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. INFI: 4.04 )
Ranked among companies with meaningful Current Ratio only.
INFI' s Current Ratio Range Over the Past 10 Years
Min: 0.64  Med: 9.03 Max: 17.81
Current: 4.04
0.64
17.81
Quick Ratio 4.04
INFI's Quick Ratio is ranked lower than
51% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.43 vs. INFI: 4.04 )
Ranked among companies with meaningful Quick Ratio only.
INFI' s Quick Ratio Range Over the Past 10 Years
Min: 0.41  Med: 8.65 Max: 17.81
Current: 4.04
0.41
17.81
Days Sales Outstanding 454.75
INFI's Days Sales Outstanding is ranked lower than
97% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: 62.58 vs. INFI: 454.75 )
Ranked among companies with meaningful Days Sales Outstanding only.
INFI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.18  Med: 16.94 Max: 831.54
Current: 454.75
0.18
831.54

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 2.79
INFI's Price/Net Current Asset Value is ranked higher than
74% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: 7.24 vs. INFI: 2.79 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
INFI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.81  Med: 2.69 Max: 398.67
Current: 2.79
0.81
398.67
Price/Tangible Book 2.10
INFI's Price/Tangible Book is ranked higher than
74% of the 1054 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. INFI: 2.10 )
Ranked among companies with meaningful Price/Tangible Book only.
INFI' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.73  Med: 2.33 Max: 46
Current: 2.1
0.73
46
Price/Median PS Value 0.62
INFI's Price/Median PS Value is ranked higher than
91% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INFI: 0.62 )
Ranked among companies with meaningful Price/Median PS Value only.
INFI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.34  Med: 0.75 Max: 13.69
Current: 0.62
0.34
13.69
Earnings Yield (Greenblatt) (%) -91.70
INFI's Earnings Yield (Greenblatt) (%) is ranked lower than
92% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. INFI: -91.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
INFI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 9.2  Med: 75.00 Max: 4204.7
Current: -91.7
9.2
4204.7

More Statistics

Revenue(Mil) $104
EPS $ -2.67
Beta2.38
Short Percentage of Float12.26%
52-Week Range $5.55 - 16.98
Shares Outstanding(Mil)49.23

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 113 141 239 84
EPS($) -2.64 -2.25 -0.51 -1.05
EPS without NRI($) -2.64 -2.25 -0.51 -1.05

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:I3F.Germany,
Infinity Pharmaceuticals Inc was incorporated in California on March 22, 1995 under the name IRORI and, in 1998; the Company changed its name to Discovery Partners International, Inc. On September 12, 2006, Discovery Partners completed a merger with Infinity Pharmaceuticals, Inc., to which a wholly-owned subsidiary of Discovery Partners merged with and into the Company. The Company is a biopharmaceutical company engaged in discovering, developing and delivering medicines to people with difficult-to-treat diseases. It combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. The IPI-145, its primary product candidate, is a potent, oral inhibitor of Class I delta and gamma isoforms of phosphoinositide-3-kinase, or PI3K. The PI3K-delta and PI3K-gamma isoforms are preferentially expressed in white blood cells, where they have distinct and mostly non-overlapping roles in immune cell development and function. For Hematologic Malignancies, the Company has launched DUETTS, an investigation of IPI-145 in blood cancers. As part of the DUETTS program, it is conducting DYNAMO, a Phase 2, open-label, single arm study evaluating the safety and efficacy of IPI-145 dosed at 25mg BID in approximately 120 patients with indolent non-Hodgkin lymphoma, or iNHL, including follicular lymphoma, marginal zone lymphoma and small lymphocytic lymphoma, whose disease is refractory to radio immunotherapy or both rituximab and chemotherapy. The FDA has granted orphan drug designation to IPI-145 for the potential treatment of follicular lymphoma. It is conducting DUO, a randomized, monotherapy Phase 3 study of IPI-145 in approximately 300 patients with relapsed/refractory chronic lymphocytic leukemia. For Inflammation and Autoimmune Diseases, the Company has completed a Phase 1, randomized, double-blind, placebo-controlled trial of IPI-145 in healthy adult subjects designed to support the development of IPI-145 in inflammatory and autoimmune diseases. The Company is also developing its second PI3K product candidate, a potent, oral inhibitor of PI3K-delta and gamma referred to as IPI-443. The nonclinical studies of IPI-443 required for Phase 1 development have been completed, and the data from the two Phase 2 studies of IPI-145 in inflammatory and autoimmune diseases will guide the next steps for the development of IPI-443. The Company has discovered IPI-940, a novel, orally available inhibitor of fatty acid amide hydrolase. It is believed that inhibition of FAAH may enable the body to bolster its own analgesic and anti-inflammatory response and may have applicability in a broad range of painful or inflammatory conditions. The Company has five issued or allowed U.S. patents covering IPI-145 and/or other molecules related to PI3K program, which expires on various dates between 2029 and 2031. In addition, it has approximately 170 patents and patent applications pending related to PI3K progr
» More Articles for INFI

Headlines

Articles On GuruFocus.com
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) Aug 04 2010 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) May 06 2010 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) Aug 06 2009 
Infinity Pharmaceuticals Inc. Reports Operating Results (10-Q) May 06 2009 

More From Other Websites
Can Infinity Pharmaceuticals (INFI) Keep the Earnings Streak Alive This Quarter? Jan 15 2016
Biotechnology Equities Scrutiny -- Advaxis, Raptor Pharma, Vanda Pharma, and Infinity Pharma Jan 14 2016
Infinity Provides Key 2016 Goals and Financial Guidance Jan 11 2016
INFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 11 2016
Infinity Provides Key 2016 Goals and Financial Guidance Jan 11 2016
Infinity to Present at J.P. Morgan Annual Healthcare Conference Jan 06 2016
Infinity to Present at J.P. Morgan Annual Healthcare Conference Jan 06 2016
Technical Coverage on Biotechnology Stocks - Agenus, Progenics Pharma, Arrowhead Research, and... Dec 28 2015
INFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Dec 22 2015
Pre-market Equity Watch on Biotechnology -- Agenus, Arrowhead Research, Spectrum Pharma, and... Dec 18 2015
INFINITY PHARMACEUTICALS, INC. Financials Dec 08 2015
How Top Money Managers Are Trading Infinity Pharmaceuticals Inc. (INFI) Dec 02 2015
What do Hedge Funds Think of Zumiez Inc. (ZUMZ)? Nov 28 2015
Inovio Pharmaceuticals Inc (INO): Hedge Fund Sentiment Unchanged Nov 25 2015
Medidata's RBM Solution Picked by Infinity Pharmaceuticals Nov 24 2015
Medidata's Risk-Based Monitoring Solution Selected by Infinity Pharmaceuticals to Advance Oncology... Nov 23 2015
Perkins looks to Infinity and beyond, to becoming a commercial-stage drugmaker Nov 19 2015
Infinity (INFI) Completes Enrollment in Phase III DUO Study Nov 18 2015
Infinity Announces Completion Of Target Enrollment In DUO™, A Phase 3 Study Evaluating duvelisib... Nov 17 2015
Infinis Energy plc Half Year Financial Results for 6 months ended 30 September 2015 Nov 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK